|
Cardiomyopathy, Dilated
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Obesity
|
0.210 |
Biomarker
|
disease |
MGD |
Prox1 heterozygous mice are a new model for adult-onset obesity and lymphatic vascular disease.
|
16170315 |
2005 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Prox-1 immunohistochemistry and pulse-chase bromodeoxyuridine labeling showed that progenitors migrate aberrantly to the hilus and molecular layer after prolonged seizures and differentiate into ectopic DGCs in rat.
|
16261566 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prospero-related homeobox 1 (Prox1) transcription factor was described as a tumor-suppressor gene in liver tumors.
|
18400094 |
2008 |
|
Colon adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
|
18455124 |
2008 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
|
18455124 |
2008 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
|
18455124 |
2008 |
|
Neoplasms, Vascular Tissue
|
0.020 |
AlteredExpression
|
group |
BEFREE |
PROX1 is a negative regulator of interferon-gamma expression in T cells and also mitigates the advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.
|
20064070 |
2010 |
|
Vascular Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
PROX1 is a negative regulator of interferon-gamma expression in T cells and also mitigates the advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.
|
20064070 |
2010 |
|
Kaposi Sarcoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
PROX1 is a negative regulator of interferon-gamma expression in T cells and also mitigates the advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.
|
20064070 |
2010 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PROX1 is a negative regulator of interferon-gamma expression in T cells and also mitigates the advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.
|
20064070 |
2010 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PROX1 is a negative regulator of interferon-gamma expression in T cells and also mitigates the advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.
|
20064070 |
2010 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
PROX1 is a predictor of survival for gliomas WHO grade II.
|
21559010 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers.
|
21559010 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prospero homeobox 1 (PROX1) has been shown to function as a tumor suppressor in various types of cancer.
|
23045246 |
2012 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Prospero homeobox 1 (PROX1) has been shown to function as a tumor suppressor in various types of cancer.
|
23045246 |
2012 |
|
Malignant tumor of colon
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PROX1 was overexpressed in 43% (59/136) of colon cancer tissues and its expression was correlated with E-cadherin downregulation (P = 0.00005), advanced tumor staging (P = 0.005), and lymph node metastasis (P = 0.000009).
|
23045246 |
2012 |
|
Colon Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PROX1 was overexpressed in 43% (59/136) of colon cancer tissues and its expression was correlated with E-cadherin downregulation (P = 0.00005), advanced tumor staging (P = 0.005), and lymph node metastasis (P = 0.000009).
|
23045246 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PROX1 was overexpressed in 43% (59/136) of colon cancer tissues and its expression was correlated with E-cadherin downregulation (P = 0.00005), advanced tumor staging (P = 0.005), and lymph node metastasis (P = 0.000009).
|
23045246 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
PROX1 was overexpressed in 43% (59/136) of colon cancer tissues and its expression was correlated with E-cadherin downregulation (P = 0.00005), advanced tumor staging (P = 0.005), and lymph node metastasis (P = 0.000009).
|
23045246 |
2012 |
|
Liver carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
PROX1 is a critical factor that promotes HCC metastasis.
|
23505027 |
2013 |
|
Neoplasm Metastasis
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
PROX1 is a critical factor that promotes HCC metastasis.
|
23505027 |
2013 |
|
Squamous cell carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma.
|
24647631 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prox1 expression was significantly associated with local progression of the tumor (P = 0.0023), clinical stage (P<0.0001), lymphovessel density (LVD) (P<0.0001), nodal metastasis (P<0.0001), and worse prognosis (P<0.0001).
|
24647631 |
2014 |
|
Neoplasm Metastasis
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
Prox1 expression was significantly associated with local progression of the tumor (P = 0.0023), clinical stage (P<0.0001), lymphovessel density (LVD) (P<0.0001), nodal metastasis (P<0.0001), and worse prognosis (P<0.0001).
|
24647631 |
2014 |